A Phase 2 Open-Label Randomized Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Brief description of study
The purpose of this research study is to determine if high dose regimens of encorafenib and binimetinib are safe, and to see if both standard dose regimens and high dose regimens have positive effects in people who have melanoma brain metastases that contain a mutated gene called BRAFV600.
Clinical Study Identifier: s19-00009
ClinicalTrials.gov Identifier: NCT03911869
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.